Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Medicus Pharma’s SEC disclosures can feel like decoding lab notes. Clinical endpoints, dose-escalation tables and financing covenants pack the company’s annual report—yet each detail can shift the valuation of this oncology-focused biotech overnight. If you have ever asked, “How do I get Medicus Pharma SEC filings explained simply?” you already know the challenge.
Stock Titan turns those dense documents into clarity. Our AI delivers line-by-line context so understanding Medicus Pharma SEC documents with AI becomes second nature. Need the Medicus Pharma annual report 10-K simplified or to monitor a sudden Medicus Pharma 8-K material events explained? It’s here, refreshed the instant EDGAR posts. Key tools include:
- Real-time alerts for every Medicus Pharma Form 4 insider transactions real-time
- Concise takeaways from each Medicus Pharma quarterly earnings report 10-Q filing
- AI-powered summaries that surface trial milestones, R&D spend and funding rounds
- Downloadable tables covering Medicus Pharma executive stock transactions Form 4
Whether you’re tracking basal-cell carcinoma trial progress or assessing dilution risk, our platform connects the dots. Investors use it to spot buying patterns in Medicus Pharma insider trading Form 4 transactions, compare cash burn across quarters with our Medicus Pharma earnings report filing analysis, or review the Medicus Pharma proxy statement executive compensation before casting votes. No more hunting through PDFs—just precise, AI-driven insight when it matters.
Medicus Pharma Ltd. granted its Chief Operating Officer, Andrew A. Smith, a stock option award covering 50,000 common shares on December 16, 2025. The options carry an exercise price of
The option is scheduled to vest quarterly in four equal installments over one year, giving Smith increasing rights to purchase shares over that period. Any unexercised portion expires on December 16, 2030, aligning the executive’s potential equity ownership with the company’s longer-term performance.
Medicus Pharma Ltd. reported an insider equity award involving a company director. On December 16, 2025, the director received a stock option grant covering 25,000 common shares with an exercise price of $1.8 per share. The option is scheduled to vest quarterly in four equal installments over one year, giving the recipient rights to portions of the award every three months during that period. The option expires on December 16, 2030, and following this grant the director beneficially owns 25,000 derivative securities directly.
Medicus Pharma Ltd. director Ajay Raju reported receiving a new stock option grant. On December 16, 2025, he was granted an option to purchase 25,000 Common Shares of Medicus Pharma at an exercise price of $1.80 per share. The option is scheduled to vest quarterly in four equal installments over one year, meaning the right to purchase the shares will become available in stages rather than all at once.
The option expires on December 16, 2030, giving the director a five-year window from the grant date to exercise once vested. Following this grant, Ajay Raju beneficially owns 25,000 derivative securities in the form of this stock option, held directly.
Medicus Pharma Ltd. reported that its Chief Medical Officer, Faisal Mehmud, received a stock option grant. On 12/16/2025, he was granted an option to buy 75,000 common shares at an exercise price of $1.8 per share. The option is scheduled to vest quarterly in four equal installments over one year, giving him rights to portions of the grant over time rather than all at once. The option expires on 12/16/2030 if not exercised. This filing reflects an equity-based compensation award to a senior officer, aligning part of his compensation with the company’s share performance.
Medicus Pharma Ltd. director Sara R. May reported a new equity award in the form of stock options. On December 16, 2025, she was granted a stock option covering 25,000 common shares of Medicus Pharma.
The option has an exercise price of $1.80 per share and is scheduled to vest quarterly in four equal installments over one year, giving her rights to the shares gradually rather than all at once. The option is currently shown as directly owned and is scheduled to expire on December 16, 2030 if not exercised.
Medicus Pharma Ltd. reported that director Patrick J. Mahaffy received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of
Medicus Pharma Ltd. reported an insider equity grant involving director Larry Kaiser. On December 16, 2025, he received a stock option to purchase 25,000 common shares of Medicus Pharma at an exercise price of $1.80 per share. The option is scheduled to vest quarterly in four equal installments over one year and is listed as directly owned. According to the filing, the option expires on December 16, 2030, and following this transaction Kaiser beneficially owns 25,000 derivative securities in the form of these options.
Medicus Pharma Ltd. director Barry Fishman reported receiving a stock option grant covering 25,000 common shares on 12/16/2025. The stock option has an exercise price of $1.8 per share and is scheduled to vest quarterly in four equal installments over one year from the grant date. The option expires on 12/16/2030. Following this grant, Barry Fishman beneficially owns 25,000 derivative securities in the form of these options, held directly.
Medicus Pharma Ltd. reported that director Robert J. Ciaruffoli received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share and was granted at no upfront cost.
The option is scheduled to vest quarterly in four equal installments over one year and expires on December 16, 2030. After this grant, he beneficially owns 25,000 stock options, held directly.
Medicus Pharma Ltd. reported that its Chief Scientific Officer, Edward J. Brennan, received a stock option grant covering 50,000 common shares on December 16, 2025. The options have an exercise price of $1.8 per share and expire on December 16, 2030.
The award is scheduled to vest quarterly in four equal installments over one year, and 50,000 derivative securities are listed as beneficially owned directly following the grant.
FAQ
What is the current stock price of Medicus Pharma (MDCX)?
What is the market cap of Medicus Pharma (MDCX)?
